EpiLeukin data

Interim data from a continuing Phase II European trial of EpiLeukin showed that 9 of 12 patients evaluated remain in remission for an average of 20 months, while 3 relapsed.

Remissions were seen both in patients with first remission and in higher risk patients with one or more previous relapses. ...